This research study is evaluating the safety and efficacy of the IS-free Treg-cell
graft-engineered haplo transplant method in people with relapsed/refractory acute myeloid
leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor
allogeneic hematopoietic stem cell transplant (HSCT).
The names of the study interventions involved in this study are:
- Radiation-Total Myeloid and Lymphoid Irradiation (TMLI
- Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna)
- Infusion of haplo Treg-enriched donor cells (experimental therapy)
- Infusion of unmodified haplo donor T cells (includes cancer-fighting T effector cells)
- Infusion of haplo donor CD34+ Peripheral Blood Stem Cells